Eucaloric Carbohydrate-Restricted Diet Improves β-Cell Function in T2DM
By Elana Gotkine HealthDay Reporter
FRIDAY, Oct. 25, 2024 -- A eucaloric carbohydrate-restricted (CR) diet improves β-cell response to glucose in patients with type 2 diabetes (T2D), according to a study published online Oct. 22 in the Journal of Clinical Endocrinology & Metabolism.
Barbara A. Gower, Ph.D., from the University of Alabama at Birmingham, and colleagues examined whether a eucaloric CR diet would improve β-cell response to glucose compared with a eucaloric higher carbohydrate diet in participants with T2D. Data were included for 57 African American and European American adults with T2D not using insulin. The acute and maximal C-peptide response to glucose was assessed at baseline and after 12 weeks of controlled diet therapy.
The researchers found that diet had a significant effect on acute C-peptide response at 12 weeks (twofold greater with CR diet). A significant effect of diet was observed for maximal C-peptide (22 percent greater with CR diet). There was also a significant diet-by-race interaction, with the diet effect specific to European Americans (48 percent greater with CR diet). A significant effect of diet was seen on disposition index at 12 weeks in the oral glucose tolerance test results (32 percent greater with the CR diet).
"With the caveat that CR may be difficult for some patients, such a diet may allow patients with mild T2D to discontinue medication and enjoy eating meals and snacks that meet their energy needs while improving β-cell function, an outcome that cannot be achieved with medication," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D
THURSDAY, July 24, 2025 -- For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause...
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
Endocrine Society, July 12-15
The annual meeting of the Endocrine Society (ENDO 2025) was held from July 12 to 15 in San Francisco, attracting more than 7,000 participants, including clinicians, academicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.